Investors Home

Evofem Biosciences, Inc. (NASDAQ: EVFM) is a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (STIs). 

The Company’s first commercial product, Phexxi™ (lactic acid, citric acid and potassium bitartrate), is the first and only vaginal pH modulator approved in the United States. The New Drug Application for Phexxi was supported by data from the AMPOWER trial, a Phase 3 single-arm, open-label trial designed to assess the effectiveness of Phexxi in preventing pregnancy and its safety over 7 menstrual cycles of use in women who were using no other form of birth control. The study enrolled approximately 1,400 women at 115 study centers in the United States. The top-line data met the pre-specified primary endpoint of this trial, and Phexxi had a favorable safety profile and was well tolerated.

The Company is also advancing EVO100 into Phase 3 clinical trials for the prevention of urogenital transmission of both Chlamydia trachomatis infection (chlamydia) and Neisseria gonorrhoeae infection (gonorrhea) in women. In December 2019, Evofem reported positive, statistically significant top-line data from a double-blind placebo-controlled Phase 2b clinical trial (AMPREVENCE) evaluating EVO100 to prevent urogenital acquisition of certain sexually transmitted infections in women. This landmark study met its primary and secondary endpoints, demonstrating a 50% relative risk reduction in chlamydia infection and a 78% relative risk reduction in gonorrhea infection compared to placebo.

The Company has assembled a very strong management team with significant operational experience in the biopharmaceutical market. Specifically, our senior executives have a successful track record of developing and commercializing women’s health products including Mirena, Plan B One-Step, Yasmin, YAZ, NuvaRing, Paragard and Seasonique, among others.

No events to display
Aug 4, 2020

Evofem Biosciences, Inc., (NASDAQ: EVFM) ("Evofem" or the "Company"), a commercial stage biopharmaceutical company, today reported financial results for the three- and six- month periods ended...

Aug 3, 2020

Evofem Biosciences, Inc. (NASDAQ: EVFM) is proud to announce that CEO Saundra Pelletier was named to the PharmaVOICE 100 Most Inspiring People, an annual list of the 100 most innovative,...

Jul 23, 2020

Evofem Biosciences, Inc. (NASDAQ: EVFM) will hold a webcast and conference call to discuss the Company's financial results and business highlights for the second quarter ended June 30, 2020. Date...

Jul 15, 2020

Evofem Biosciences, Inc. (NASDAQ: EVFM), a commercial-stage biopharmaceutical company, today announced that Contraception, an international, peer-reviewed, reproductive health journal, published...

Jul 1, 2020

Evofem Biosciences, Inc. (NASDAQ: EVFM), a commercial-stage biopharmaceutical company, today announced that it has issued a letter to its stockholders providing an update on recent events and...

Read More